pubmed-article:14678339 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0032659 | lld:lifeskim |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
pubmed-article:14678339 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
pubmed-article:14678339 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:14678339 | pubmed:dateCreated | 2003-12-17 | lld:pubmed |
pubmed-article:14678339 | pubmed:abstractText | Previous pharmacokinetic studies of the 3-weekly regimen (100 mg m(-2) every 3 weeks) of docetaxel have shown that docetaxel clearance is affected by liver function, body surface area, age, serum alpha1-acid glycoprotein and cytochrome P450 3A4 (CYP3A4) activity. However, the pharmacokinetics of a weekly docetaxel (40 mg m(-2) week(-1)) schedule are not well characterized. The aims of this study were (a) to investigate the pharmacokinetics of docetaxel (40 mg m(-2) week(-1)) using sparse concentration-time data collected from patients with advanced cancer and (b) to utilize a population pharmacokinetic approach to identify patient covariates that significantly influence the clearance of docetaxel when administered according to this regimen. | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:language | eng | lld:pubmed |
pubmed-article:14678339 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:14678339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:14678339 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:14678339 | pubmed:month | Jan | lld:pubmed |
pubmed-article:14678339 | pubmed:issn | 0306-5251 | lld:pubmed |
pubmed-article:14678339 | pubmed:author | pubmed-author:RivoryLaurent... | lld:pubmed |
pubmed-article:14678339 | pubmed:author | pubmed-author:McLachlanAndr... | lld:pubmed |
pubmed-article:14678339 | pubmed:author | pubmed-author:ClarkeStephen... | lld:pubmed |
pubmed-article:14678339 | pubmed:author | pubmed-author:SlavieroKelli... | lld:pubmed |
pubmed-article:14678339 | pubmed:author | pubmed-author:BlairElaine... | lld:pubmed |
pubmed-article:14678339 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:14678339 | pubmed:volume | 57 | lld:pubmed |
pubmed-article:14678339 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:14678339 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:14678339 | pubmed:pagination | 44-53 | lld:pubmed |
pubmed-article:14678339 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:meshHeading | pubmed-meshheading:14678339... | lld:pubmed |
pubmed-article:14678339 | pubmed:year | 2004 | lld:pubmed |
pubmed-article:14678339 | pubmed:articleTitle | Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. | lld:pubmed |
pubmed-article:14678339 | pubmed:affiliation | Department of Pharmacology, University of Sydney, 2006, NSW, Australia. | lld:pubmed |
pubmed-article:14678339 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:14678339 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:14678339 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14678339 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14678339 | lld:pubmed |